Our experience in GMP manufacturing of complex and sophisticated cell-based therapies with global reach can support your program. We offer licensed GMP manufacturing for autologous and allogeneic cell therapy products throughout the development pipeline, from translational first-in-human clinical studies to late-phase trials and commercial supply.
Our two decades of experience span autologous and allogeneic therapies across a wide range of cell types, including chimeric antigen receptor (CAR) T-cells, mesenchymal stromal cells, tumour-infiltrating lymphocytes (TILs), and human pluripotent stem cells and their derivatives.